



Gatot Soegiarto <gatot_soegiarto@fk.unair.ac.id>

Your Submission

1 message

Annals of Medicine and Surgery <em@editorialmanager.com>
Reply-To: Annals of Medicine and Surgery <annalsjournal@elsevier.com>
To: Gatot Soegiarto <gatot_soegiarto@fk.unair.ac.id>

10 August 2022 at 00:18

Ms. Ref. No.: AMSU-D-22-01229
Title: Management of Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome in a Female Indonesian with Pulmonary Tuberculosis: A Rare Case
Annals of Medicine and Surgery

Dear Mr Soegiarto,

The Editor and reviewer have commented on your above paper. They indicated that it is not acceptable for publication in its present form.

However, if you feel that you can suitably address the Managing Editor (if applicable) and Reviewer(s) comments (included below), I invite you to revise and resubmit your manuscript.

Please carefully address the issues raised in the comments.

If you are submitting a revised manuscript, please also:

a) outline each change made (point by point) as raised in the reviewer comments

AND/OR

b) provide a suitable rebuttal to each reviewer comment not addressed

c) Supply a revised manuscript with track changes - Your revised manuscript with track changes added or your revisions highlighted in bold/red.

d) Supply a revised manuscript un-tracked - A clean unmarked copy of your revised manuscript.

To submit your revision, please do the following:

1. Go to: <https://www.editorialmanager.com/amsu/>
2. Enter your login details
3. Click [Author Login]
This takes you to the Author Main Menu.
4. Click [Submissions Needing Revision]

I look forward to receiving your revised manuscript.

Yours sincerely,

Dr Riaz Agha
Editor-in-Chief
Annals of Medicine and Surgery

Reviewer(s) comments:

Managing Editor

Please can you make the following changes/checks:

1. Please ensure your case report is compliant with the SCARE Guidelines 2020: <http://www.scareguideline.com> and submit a completed SCARE 2020 checklist.

Please pay particular attention to the following criteria which are often missed:

- Who performed the procedure? (item 9d)
- patient perspective (item 12)
- Drug history, family history including any relevant genetic information, and psychosocial history (item 5d)

- Where relevant - intervention adherence and tolerability (item 10c)
- Post-intervention considerations (item 9f)

2. Please also ensure you state that the work has been reported in line with the SCARE 2020 criteria:

Agha RA, Franchi T, Sohrabi C, Mathew G, for the SCARE Group. The SCARE 2020 Guideline: Updating Consensus Surgical Case Report (SCARE) Guidelines, *International Journal of Surgery* 2020;84:226-230.

3. Please cite the SCARE 2020 paper above in your text in the methods section and add the reference to your references section.

4. Please ensure you submit a structured abstract with sub-headings as follows:
Introduction and importance, Case presentation, clinical Discussion, Conclusion

5. Can you also please ensure you go through the entire manuscript and check the spelling, grammar and syntax and ensure the language is concise. If you need our author support services, you can access them here:
<https://www.ijspg.com/services/author-support>

6. Please be very clear about what this adds to the existing literature and clearly detail learning points.

7. Please ensure you submit your work with a Research Registry unique identifying number (UIN) if its first in man i.e. the first time a new device or surgical technique is performed: www.researchregistry.com – it can't progress without being registered. Please ensure you also state your registration UIN in your methods section and reference it including a hyperlink to it if registration is appropriate.

8. If you haven't already, please include your "highlights" which are 3-5 bullet points summarising the novel aspects and/or learning points (maximum 85 characters, including spaces, per bullet point).

9. The consent statement in the author form is not suitable. We need a statement like this:

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Please see consent section in instructions to authors for further information.

10. Please ensure any images/figures/photos are suitably anonymised with no patient information or means of identifying the patient.

11. Please add a Guarantor on the Author form, if you haven't already.

The guarantor is that individual who accepts full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish.

12. Please add the following statement above references:

Provenance and peer review
Not commissioned, externally peer-reviewed

13. Above references, please state the following headings with your response (if something doesn't apply, say N/a or none or none declared):

- conflicts of interest
- sources of funding
- ethical approval
- consent
- author contribution
- research registration (for case reports detailing a new surgical technique or new equipment/technology)
- Guarantor

14. Author Form

Please ensure that you have completed and uploaded the correct author form for IJS Case Reports: https://www.elsevier.com/___data/promis_misc/2020_IJSCR_Author_Disclosure_Form.docx.

Please also make sure that you complete each section of the form.

Or for AMS:

https://www.elsevier.com/___data/promis_misc/2020_AMSU_Author_Disclosure_Form.docx

Reviewer #1: * Author needs to add case report as keyword according to The SCARE 2020 Guidelines.

* The use of abbreviations like. DRESS, AST, ALT.... and others should be written in full the first time they are used in the manuscript.

Case Presentation

* Line 7 "" leucocytosis with a white blood cell count of 16,270/L."" The unit used here and in other places were wrong units. Must be corrected.

* Author has to be systematic. He must document all important points in history first then he can discuss the investigation. Putting X ray findings in the middle of history findings is not acceptable (like what is found in line 24,25, 1).

* Nothing was mentioned about family history. This is important as the risk of DRESS may be as high as 25% in individuals who have a first degree relative who has experienced this syndrome.

*

Discussion

- * Risk factors for DRESS syndrome need a detailed discussion .
 - * Author is required to refer to (RegiSCAR criteria). He can put it as a figure.
- Figures and legends
- * The legend of figure 1 is incomplete. It must include the findings of the chest X ray.
- Good luck

Please note that the editorial process varies considerably from journal to journal. To view the submission-to-publication lifecycle, click here: http://help.elsevier.com/app/answers/detail/p/7923/a_id/160

For further assistance, please visit our customer support site at <http://help.elsevier.com/app/answers/list/p/7923>. Here you can search for solutions on a range of topics, find answers to frequently asked questions and learn more about EM via interactive tutorials. You will also find our 24/7 support contact details should you need any further assistance from one of our customer support representatives.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/amsu/login.asp?a=r>). Please contact the publication office if you have any questions.

Publishing Agreement completed for your article [AMSU_104512]

1 message

Elsevier - Author Forms <Article_Status@elsevier.com>

25 August 2022 at 12:36

To: gatot_soegiarto@fk.unair.ac.id

Cc: gatot_soegiarto@fk.unair.ac.id

ELSEVIER

Dear Mr Soegiarto,

Thank you for completing the Publishing Agreement Form for your article *Management of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in a female Indonesian with pulmonary tuberculosis: A rare case report*. Please find attached a copy of the "Journal Publishing (License) Agreement" which you completed online on August 25, 2022.

If you have any questions, please do not hesitate to contact us. To help us assist you, please quote our article reference AMSU_104512 in all correspondence.

Now that your article has been accepted, you will want to maximize the impact of your work. Elsevier facilitates and encourages authors to share their article responsibly. To learn about the many ways in which you can share your article whilst respecting copyright, visit: www.elsevier.com/sharing-articles.

We are committed to publishing your article as quickly as possible.

Kind regards,


Elsevier Researcher Support


Have questions or need assistance?

Please do not reply to this automated message.

For further assistance, please visit our [Elsevier Support Center](#) where you search for solutions on a range of topics and find answers to frequently asked questions.

You can also talk to our researcher support team by phone 24 hours a day from Monday-Friday and 24/7 by live chat and email.

© 2022 Elsevier Ltd | [Privacy Policy](http://www.elsevier.com/privacypolicy) <http://www.elsevier.com/privacypolicy>Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom, Registration No. 1982084. This e-mail has been sent to you from Elsevier Ltd. To ensure delivery to your inbox (not bulk or junk folders), please add Article_Status@elsevier.com to your address book or safe senders list.

 **AMSU104512.html**
19K

Rights and Access form completed for your article [AMSU_104512]

1 message

Elsevier - Author Forms <Article_Status@elsevier.com>
To: gatot_soegiarto@fk.unair.ac.id

25 August 2022 at 12:36

ELSEVIER

Dear Mr Soegiarto,

Thank you for completing the Rights and Access Form for your article *Management of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in a female Indonesian with pulmonary tuberculosis: A rare case report* on August 25, 2022.

The Order Summary is attached to this email.

Your article will be free for everyone to read online as soon as it is published.

If you have any questions, please do not hesitate to contact us. To help us assist you, please quote our article reference AMSU_104512 in all correspondence.

Now that your article has been accepted, you will want to maximize the impact of your work. Elsevier facilitates and encourages authors to share their article responsibly. To learn about the many ways in which you can share your article whilst respecting copyright, visit: www.elsevier.com/sharing-articles.

Kind regards,
Elsevier Researcher Support

**Seven strategies for you to create a brand and promote your research**

Learn how to give your research the visibility it deserves with these seven strategies.

> [Access module now](#)

Have questions or need assistance?

Please do not reply to this automated message.

For further assistance, please visit our [Elsevier Support Center](#) where you search for solutions on a range of topics and find answers to frequently asked questions.

You can also talk to our researcher support team by phone 24 hours a day from Monday-Friday and 24/7 by live chat and email.

© 2022 Elsevier Ltd | [Privacy Policy](http://www.elsevier.com/privacypolicy) <http://www.elsevier.com/privacypolicy>

Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom, Registration No. 1982084. This e-mail has been sent to you from Elsevier Ltd. To ensure delivery to your inbox (not bulk or junk folders), please add Article_Status@elsevier.com to your address book or safe senders list.

2 attachments**Order Confirmation.html**

15K



Terms and Conditions of Sale and Purchase.pdf

585K

PLEASE TAKE ACTION - Share your article [AMSU_104512]

1 message

Elsevier - Article Status <Article_Status@elsevier.com>
To: gatot_soegiarto@fk.unair.ac.id


1 September 2022 at 17:01

ELSEVIER**Share your article!**

Dear Mr Soegiarto,

We are pleased to let you know that the final open access version of your article *Management of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in a female Indonesian with pulmonary tuberculosis: A rare case report* is now available online, containing full bibliographic details.

The URL below is a quick and easy way to share your work with colleagues, co-authors and friends. Anyone clicking on the link will be taken directly to the final version of your article on ScienceDirect.



Your article link:

<https://doi.org/10.1016/j.amsu.2022.104512>

Click on the icons below to share with your network:



You can also use this link to download a copy of the article for your own archive. It also provides a quick and easy way to share your work with colleagues, co-authors and friends. And you are welcome to add it to your homepage or social media profiles, such as Facebook, Google+, and Twitter. Other ways in which you can use your final article have been determined by your choice of [user license](#).

To find out how else you can share your article visit www.elsevier.com/sharing-articles.

Kind regards,
Elsevier Researcher Support

Increase your article's impact

Our [Get Noticed](#) guide contains a range of practical tips and advice to help you maximize visibility of your article.

Publishing Lab

Do you have ideas on how we can improve the author experience? Sign up for the [Elsevier Publishing Lab](#) and help us develop our publishing innovations!

Have questions or need assistance?

Please do not reply to this automated message.

For further assistance, please visit our [Elsevier Support Center](#) where you search for solutions on a range of topics and find answers to frequently asked questions.

You can also talk to our researcher support team by phone 24 hours a day from Monday-Friday and 24/7 by live chat and email.

19/12/22 13.19

Airlangga University Mail - PLEASE TAKE ACTION - Share your article [AMSU_104512]

© 2022 Elsevier Ltd | [Privacy Policy](http://www.elsevier.com/privacypolicy)
Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom,
Registration No. 1982084. This e-mail has been sent to you from Elsevier Ltd. To ensure delivery to your
inbox (not bulk or junk folders), please add Article_Status@elsevier.com to your address book or safe
senders list.